Kurt Graves, Intarcia
Intarcia's speed bump at the FDA turns into a roadblock, as regulators once again turn thumbs down on diabetes drug/device
Back in the fall of 2017, Intarcia CEO Kurt Graves handled the FDA’s rejection of its hotly promoted drug/device as something of a speed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
